Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment.

Abstract

Even with normal baseline liver biochemical tests, HCV co-infection had a higher incidence and longer exacerbations of hepatitis during anti-tuberculosis treatment. We suggest that screening for HCV infection before starting anti-tuberculosis treatment is helpful in planning the frequency of follow-up visits.